ERCC1 (excision repair cross complementation group 1) is a subunit of the nucleotide excision repair complex, which can perform DNA strand incision correction of DNA damage. Association studies on the ERCC1 polymorphisms (C8092A and T19007C) in cancer had shown conflicting results. We performed a meta-analysis from all eligible case-control studies to assess the purported associations. Overall, the 19007C allele (3 853 patients and 4 349 controls) showed no significant effect on cancer risk compared to 19007T allele (P ¼ 0.39, odds ratio (OR) ¼ 0.95; 95% confidence interval (CI) 0.85 -1.06, P heterogeneity ¼ 0.001) in all subjects. Meta-analysis under other genetic contrasts did not reveal any significant association of T19007C to cancer in all subjects, Caucasians and Asians. The 19007C allele (2 279 patients and 2 808 controls) showed no significant effect on lung cancer risk compared to 19007T allele (P ¼ 0.72, OR ¼ 0.94, 95% CI 0.69-1.29, P heterogeneity ¼ 0.0001) in all subjects. No significant effect of 8092A allele (3 865 patients and 3 750 controls) on cancer risk in all subjects (P ¼ 0.85, OR ¼ 1.01, 95% CI 0.94 -1.08, P heterogeneity ¼ 0.92) and in Caucasians and Asians compare to 8092C. No evidences of association of C8092A (501 patients and 620 controls) to squamous cell carcinoma were found. The accumulated evidence indicated ERCC1 T19007C and C8092A might not be risk factors for cancer. Significant betweenstudy heterogeneity existed in T19007C, which arose from a study showing significant protecting effect of 19007C allele compare to 19007T allele in smokers. More studies based on larger, stratified case-control population should be required to further evaluate the role of ERCC1 C8092A and T19007C polymorphisms in different cancer, especially in smokers.
Introduction
DNA in most cells is regularly damaged by chemical and physical agents in the environment such as smokingrelated carcinogens and DNA lesions caused by shortwave UV component of sunlight. 1 Unrepaired DNA damage may lead to the loss of genomic integrity, unregulated cell growth and ultimately cancer. Thus, genes coding for DNA repair proteins have been proposed as candidate cancer-susceptibility genes. NER (Nucleotide excision repair) is the component of the intricate network of DNA repair systems, which repairs bulk adducts lesions. ERCC1 (excision repair cross complementation group 1) is a subunit of the NER complex, which can recognize DNA damage, form heterodimers with XPF proteins, and then perform DNA strand incision. 2, 3 Defect in ERCC1 had been reported to be associated with the most severe DNA repair deficiency among NER pathway genes.
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C8092A (rs3212986) and T19007C (rs11615) are two common polymorphisms of ERCC1. The C8092A polymorphism is located in the 3 0 -untranslated region of the gene and may affect ERCC1 messenger RNA stability. 5 The synonymous T19007C polymorphism at codon 118 (Asn118Asn) may be associated with a reduction in expression of ERCC1 mRNA levels and subsequently a decreased level of ERCC1 protein. 6 In recent years, many studies in cancer epidemiology focused on the associations between cancer risks and DNA-repair pathway gene SNPs, including genes in NER pathway. However, studies on the polymorphism of ERCC1 T19007C polymorphisms had shown conflicting results; studies on ERCC1 C8092A polymorphisms had shown different trends of risk in cancer, but none of the result was significant. Potential contribution of differences in patient populations (eg, age and years from onset, sex, disease severity, smoking, or diet status) might cause different results, and association can only be found in stratification analysis. Considering the possible small effect size of those two polymorphisms to cancer risk and the relatively small sample size in each study, it is important to perform a quantitative synthesis of the evidence with rigorous methods. Here, we performed a meta-analysis from all eligible case -control studies to address the association of ERCC1 C8092A and T19007C polymorphisms to cancer.
Materials and methods

Identification and eligibility of relevant studies
To identify all articles that examined the association of ERCC1 C8092A and T19007C polymorphisms with cancer, we conducted a literature search of PubMed database (from January 1991 to October 2006) using the following keywords and subject terms: 'ERCC1', 'polymorphism', and 'cancer'. References of retrieved articles were screened. Abstracts, case reports, editorials, and review articles were excluded. Studies included in the current meta-analysis had to meet all the following criteria: (a) use an unrelated case -control design, (b) have available genotype frequency and (c) genotype distribution of control population must be in Hardy -Weinberg equilibrium (HWE).
Data extraction
Data were collected on the genotype of C8092A and T19007C according to different kinds of cancers. First author, year of publication, ethnicity of study population, and characteristics of cases and control were described.
Statistical analysis
Odds ratios (OR) corresponding to 95% confidence interval (CI) was applied to assess the strength of association of C8092A and T19007C with cancers as case -control studies were used, and OR was calculated according to the method of Woolf. 7 A w 2 -based Q statistic test was performed to assess the between -study heterogeneity. 8 Heterogeneity was considered significant for Po0.10 because of the low Publication bias was investigated by funnel plot, in which the standard error of log (OR) of each study was plotted against its OR. An asymmetric plot suggested possible publication bias. Funnel plot asymmetry was assessed by the method of Egger's linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of the OR. 10 The significance of the intercept was determined by the t-test as suggested by Egger, and a P-value of o0.05 was considered significant. HWE was tested by the w 2 -test for goodness of fit using a web-based program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Analyses were performed using the software Stata version 7, ReviewManage 4.2. All P-values were two-sided.
Results
Selection of studies
The most popular SNP studied of ERCC1 were C8092A and T19007C; articles about SNPs other than these two were discarded in our selection of studies. A total of 21 articles were retrieved based on the searching criteria for cancer susceptibility related to these two SNPs, and 15 met our inclusion criteria. Out of these 15 eligible articles 10 described T19007C 11 -20 and 9 of the 14 eligible articles Overall effects for alleles Significant heterogeneity existed in 13 studies when compared T19007C T vs C allele in different kinds of cancers ( Table 2 ). The random effects model was used to pool the result (Figure 1a ). There was no evidence that the C allele associated with the risk of cancer in all subjects. The summary OR was 0.95, 95% CI (0.85 -1.06) by random effects (P ¼ 0.39) with P heterogeneity ¼ 0.001 (Table 2) . A sensitivity analysis showed that the study by Zienolddiny et al 12 was the main cause of the heterogeneity. After exclusion of this study, the heterogeneity was no longer significant (P heterogeneity ¼ 0.13), and the estimated overall effect remained insignificant (P ¼ 0.89, OR ¼ 1.00, 95% CI (0.94 -1.06) by fixed effect). Table 2 ). The between-study heterogeneity remained after exclusion the study of Zienolddiny et al 12 (P ¼ 0.93, OR ¼ 1.00, 95% CI (0.90 -1.12), P heterogeneity ¼ 0.05), which indicated other studies contribute to the heterogeneity in Caucasians.
No significant heterogeneity existed in 10 studies when compared C8092A A vs C allele in different kinds of cancers ( Table 2) . The fixed effect model was used to pool the result (Figure 2a) . There was no evidence that the 8092A allele associated with the risk of cancer in all subjects, Caucasians, and Asians, with the summary OR ¼ 1.01, 95% CI (0.94 -1.08) P ¼ 0.85, P heterogeneity ¼ 0.92; OR ¼ 0.99, 95% CI (0.91 -1.09) P ¼ 0.90, P heterogeneity ¼ 0.55; OR ¼ 1.00, 95% CI (0.74 -1.34) P ¼ 1.00, P heterogeneity ¼ 0.87, respectively (Table 2) .
Three out of 10 studies including 501 patients and 620 controls examined the association of C8092A to squamous cell carcinoma risk, but no association of 8092A to squamous cell carcinoma risk was found (Figure 2b , P ¼ 0.58, OR ¼ 0.95, 95% CI (0.78 -1.15), P heterogeneity ¼ 0.88, Table 2 ).
Other genetic contrasts Meta-analysis under other genetic contrasts (dominant, recessive, and additive genetic models) suggested that the 19007C showed no association to cancer risk in all subjects, Caucasians, and Asians, as well as the association between T19007C and lung cancer in the genetic models in all subjects (Table 2 ). 8092A showed no association to cancer risk under different genetic models in all subjects, Caucasians and Asians. No evidence of association between 8092A and squamous cell carcinoma was discerned as we compared other genetic models (Table 2) . No single study (2006) Sugimura (2006) Yang (2006) Yang (2006) Zienolddiny ( ERCC1 polymorphisms Y Li et al influenced the pooled ORs as reveal by sensitivity analysis (data not shown), which further confirmed that no association of the T19007C and C8092A polymorphisms to cancer risk.
Publication bias
Egger's test provided no evidence for funnel plot asymmetry in the comparison of 19007C allele vs 19007T allele in the OR analysis in overall cancer (t ¼ À0.50, P ¼ 0.63). Similarly, no publication bias was detected for A vs C contrast of C8092A polymorphism in overall cancer (t ¼ À0.80, P ¼ 0.45). Figure 3 showed the Begg's funnel plot of the Egger's test.
Discussion
In the analysis of ERCC1 T19007C polymorphisms to susceptibility of cancer, significant between-study heterogeneity was found in all the comparisons except in the recessive genetic model (CC vs (CT þ TT) (P heterogeneity ¼ 0. 15). Sensitivity analysis showed the study of Zienolddiny et al 12 was the origin of the heterogeneity in all subjects.
In the Caucasian subgroup analysis, the between-study heterogeneity remained after exclusion the study of It is possible that the association between ERCC1 polymorphisms and cancer risk might be modified by smoking. However, no sufficient studies available to do such an analysis so far. More careful stratification analyses according to the smoking status and cancer types are needed; meta-regression analysis is then possible to reveal the risk of smoking in cancer.
Different studies showed different trend of effect of the C8092A polymorphism on the risk of different kinds of cancers, which reflected by the OR value (below 1 or above 1), but none of them had a significant effect. No betweenstudy heterogeneity existed among different cancer types. Potential contribution of differences in patient populations (eg, age and years from onset, gender difference, and cancer types) did not affect the overall effect of C8092A polymorphism.
DNA repair is known as a 'double-edged sword' in cancer. Impaired DNA repair capacity may increase risk of cancer, but meanwhile induce resistance to the antitumor activity of platinum-DNA adducts. 25 Platinum-based chemotherapy induced DNA damage (inter-/intrastrand crosslinking) by forming platinum-DNA adducts and causes cell death. 26 Increased tolerance to DNA damage, resulting from a highly efficient DNA-repair capacity, 27 is one of the 30 Thus, Alterations in the function of ERCC1 may affect DNA repair proficiency and influence cancer patients' response to cisplatin. ERCC1 T19007C and C8092A polymorphisms may not confer a significant effect in the susceptibility of cancer, but they may play an important role in the drug sensitivity of platinum-based chemotherapy.
In conclusion, our meta-analysis suggests that the ERCC1 T19007C and C8092A polymorphisms had no association to cancer risk. However, significant between-study heterogeneity did exist in the analysis T19007C allele, which results from a study using smokers of matched cases and controls in lung cancer. 12 More studies or large casecontrol studies, especially studies stratified for smokinggenotyping interaction should be performed to clarify possible roles of T19007C and C8092A in different kinds of cancer.
